Filing Flows › Comparisons › EVMN vs ZBIO
Evommune vs Zenas BioPharma: EVMN and ZBIO compared
Evommune is the larger company: $10.0M of revenue in its latest quarter (Q3 2025) against $10.0M for Zenas BioPharma (Q3 2026).
Where the money goes: EVMN and ZBIO
Evommune (EVMN) · Q3 2025
Evommune, Q3 2025: revenue $10.0M, operating margin -133.3%, net loss $12.5M, operating cash flow −$9.6M. The chart follows the revenue to costs, profit and cash.
Zenas BioPharma (ZBIO) · Q3 2026
Zenas BioPharma, Q3 2026: revenue $10.0M, net loss $109M, operating cash flow −$58.0M. The chart follows the revenue to costs, profit and cash.
| Evommune (EVMN) | Zenas BioPharma (ZBIO) | |
|---|---|---|
| Latest quarter | Q3 2025 | Q3 2026 |
| Revenue | $10.0M | $10.0M |
| Operating margin | -133.3% | n/m |
| Net earnings | −$12.5M | −$109M |
| Net margin | -124.8% | — |
| Operating cash flow | −$9.6M | −$58.0M |
Questions
Which is bigger, Evommune or Zenas BioPharma?
Evommune is the larger company: $10.0M of revenue in its latest quarter (Q3 2025) against $10.0M for Zenas BioPharma (Q3 2026).
More: Evommune earnings · how Evommune makes money · Zenas BioPharma earnings · how Zenas BioPharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Dec 11, 2025; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.